The estimated Net Worth of Israel Gp Ltd.Orbi Med Isra... is at least $23.8 Million dollars as of 23 June 2021. Israel Isra owns over 17,150,781 units of 9 Meters Biopharma stock worth over $599,618 and over the last 8 years Israel sold NMTR stock worth over $23,153,073.
Sign up
Israel Isra NMTR stock SEC Form 4 insiders trading
Israel has made over 3 trades of the 9 Meters Biopharma stock since 2019, according to the Form 4 filled with the SEC. Most recently Israel sold 17,150,781 units of NMTR stock worth $20,923,953 on 23 June 2021.
The largest trade Israel's ever made was selling 17,150,781 units of 9 Meters Biopharma stock on 23 June 2021 worth over $20,923,953. On average, Israel trades about 1,790,019 units every 78 days since 2017. As of 23 June 2021 Israel still owns at least 8,565,974 units of 9 Meters Biopharma stock.
You can see the complete history of Israel Isra stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at 9 Meters Biopharma
Over the last 5 years, insiders at 9 Meters Biopharma have traded over $20,934,964 worth of 9 Meters Biopharma stock and bought 2,247,050 units worth $1,572,701 . The most active insiders traders include Israel Gp Ltd.Orbi Med Isra..., Mark A Sirgo und John Temperato. On average, 9 Meters Biopharma executives and independent directors trade stock every 35 days with the average trade being worth of $45,283. The most recent stock trade was executed by Bethany Sensenig on 21 April 2023, trading 9,100 units of NMTR stock currently worth $11,011.
What does 9 Meters Biopharma do?
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.
What does 9 Meters Biopharma's logo look like?
Complete history of Israel Isra stock trades at Novus Therapeutics Inc und 9 Meters Biopharma
9 Meters Biopharma executives and stock owners
9 Meters Biopharma executives and other stock owners filed with the SEC include:
-
John Temperato,
Pres, CEO & Director -
Dr. Patrick H. Griffin,
Chief Medical Officer -
Edward J. Sitar CPA, CPA,
Chief Financial Officer -
Sarah Liu M.B.A.,
Chief Commercial Officer -
Albert J. Medwar M.B.A., MBA,
Sr. VP of Investor Relations & Corp. Communications -
Bethany Sensenig C.M.A., M.B.A.,
Chief Financial Officer -
Dr. Nir Barak M.D.,
Sr. VP of Scientific Affairs -
Dr. Elena Verdu M.D., Ph.D.,
Clinical & Scientific Advisor and Consultant -
Dr. Ciaran P. Kelly M.D.,
Clinical & Scientific Advisor and Consultant -
Joseph A. Murray,
Clinical & Scientific Advisor and Consultant -
Dr. Peter H. R. Green M.D.,
Clinical & Scientific Advisor and Consultant -
Dr. Nir Barak,
Sr. VP of Scientific Affairs -
Jerry Gardner,
Head of Clinical Strategy -
Sireesh Appajosyula Pharm.D.,
Sr. VP of Corp. Devel. & Operations -
Samantha Ventimiglia,
Director -
Bethany Sensenig,
Chief Financial Officer -
John Temperato,
Chief Executive Officer -
Edward J Sitar,
Chief Financial Officer -
Lorin K Johnson,
Director -
Israel Gp Ltd.Orbi Med Isra...,
-
Nissim Darvish,
Director -
Sandeep Laumas,
Director -
Mark A Sirgo,
Director -
Saira Ramasastry,
Director -
Roy Proujansky,
Director -
Yehuda Michael Rice,
Director -
Jay P. Madan,
President -
Anthony E Iii Maida,
Director -
Michael T. Constantino,
Director